内质网分子伴侣29在胃癌中的表达及临床意义研究

Expression and Clinical Significance of ERp29 in Gastric Carcinoma

目的探讨ERp29在胃癌中的表达及其与临床病理特征、预后等之间的关系。方法通过免疫组化检测胃癌组织及癌旁组织中ERp29的表达情况,并分析ERp29与临床病理特征及预后的相关性。结果 ERp29在胃癌旁组织及癌组织中的阳性表达率分别为为80.48%(66/82)、45.12%(37/82),两者相比差异具有统计学意义(P<0.05)。ERp29的表达与患者年龄、性别、肿瘤部位、癌组织学类型及局部浸润深度等无明显相关性,但与肿瘤TNM分期及淋巴结转移呈负相关。ERp29表达阳性患者的3年生存率、平均生存期均高于阴性组患者。结论胃癌组织ERp29的表达下降,并且与肿瘤的临床病理特征及预后相关,提示ERp29是一个潜在抑癌基因。

Objective To explore the expression of ERp29 in gastric carcinoma and its relationship with clinical and patho- logical features and prognosis of patients. Methods The expression of the ERp29 in gastric carcinoma cancer and adjacent nor- mal tissue was detected with immunohistochemical method and its correlation to the clinical pathological features and prognosis were analyzed. Results The positive expression rate of ERp29 was 80.48 % （66/82） in adjacent tissue and 45.12% （37/82） in cancer tissues （ P 〈 0.05 ）. There was no significant correlation between ERp29 and patient＇ s age, sex, tumor location, cancer his- tological type and depth of local invasion, but a negative correlation with TNM stage and lymph node metastasis. The 3-year sur- vival rate and average survival of patients with positive ERp29 expression was longer than the patients with a negative expression of ERp29. Conclusion The expression of ERp29 in gastric tissue decreases, and is associated with the clinical and pathological features and the prognosis of patients ; this prompted ERp29 may be a potential tumor suppressor gene.